Print Page     Close Window     

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent NewsMore
06/01/18
Seres Therapeutics to Present at Two Upcoming June Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 1, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced it will present at each of the following upcoming healthcare conferences: Jefferies 2018 Global Healthcare Conference: a corporate overview will be presented on Wednesday, June 6 at 4:30 p.m. ET in New York, NY. Goldman Sachs 39th Annual Global Healthcare Conference: a corporate overview will be ... 
05/17/18
Seres Therapeutics to Host Microbiome R&D Event and Webcast on May 24, 2018
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 17, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that the Company will host a Microbiome R&D Day on Thursday, May 24, 2018, from 8:00 a.m.–10:30 a.m. ET in New York, NY. The event will feature presentations from Seres management and leading academic subject matter experts on the microbiome as a new therapeutic target, with a focus on the Seres pipeline and the opportunity for ... 
05/09/18
Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Updates
– Preclinical data provide mechanistic insights related to the potency of microbiome therapeutics to augment immuno-oncology treatments; initiation of clinical study in metastatic melanoma planned for later this year – – FDA dialogue ongoing to support development of SER-287 for Ulcerative Colitis; Company plans to initiate clinical trial in mid-2018 – – Company to host Microbiome R&D Day on May 24 in New York City – ... 
EventsMore
Download DocumentationCorporate Presentation

There are currently no upcoming events scheduled.
Stock Quote
NASDAQ:MCRB
$8.03
0.00 (0.00%)
07/16/18 4:00 p.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

More
Data provided by Nasdaq. Minimum 15 minutes delayed.

© Seres Therapeutics. All Rights Reserved.